Congress on the Future of Breast Cancer

Finding Actionable Biomarkers Like ESR1 and PIK3CA in Metastatic Breast Cancer to Drive Precision Medicine

July 23, 2017

The challenge of precision medicine in metastatic breast cancer is to develop well-tolerated therapies based on key actionable, accessible, and validated biomarkers, said Francisco J. Esteva, MD, PhD, during an explanation of the current understanding of the molecular landscape of metastatic breast cancer at the 16th Annual International Congress on the Future of Breast Cancer East.

Improving Responses, Minimizing Toxicity Goal of Trastuzumab Combinations in HER2+ Breast Cancer

July 22, 2017

In the neoadjuvant and adjuvant settings of treating patients with HER2-positive breast cancer, trastuzumab (Herceptin) remains a standard of care. The question has become whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in this patient population without added toxicities, according to Sara M. Tolaney, MD, MPH.

Checkpoint Inhibitors Moving Ahead in Breast Cancer

July 22, 2017

Checkpoint inhibitors against PD-1 and PD-L1 have demonstrated promising efficacy as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer, with phase III data on the horizon

Pegram Highlights a New Renaissance of Research in HER2-Positive Metastatic Breast Cancer

July 21, 2017

Mark Pegram, MD, shares some of the most recent developments in the HER2-positive metastatic breast cancer space, the research currently ongoing, and why it is such an exciting time for the field.

O'Shaughnessy Shares Novel Therapeutic Strategies for Treating Metastatic TNBC

July 21, 2017

Joyce O’Shaughnessy, MD, provides an update on existing research in metastatic triple-negative breast cancer, and novel agents on the horizon.

Age is Not All-Telling When Treating Older Adults With Breast Cancer, Expert Says

July 21, 2017

In an interview with Targeted Oncology, Arti Hurria, MD, shares the treatment considerations she makes when treating older patients with breast cancer, the unique challenges that come with treating this patient population, and the exciting future she envisions for this space.

Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast Cancer

July 19, 2017

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant endocrine therapy for patients with HR+ breast cancer.

Utilizing Genomic Assays for Decision Making in Early Stage Breast Cancer

July 19, 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the utility of molecular signatures in managing early-stage breast cancer.

An Overview of the MA17R Trial in Breast Cancer

July 29, 2016

Frankie Ann Holmes, MD, medical oncologist, Texas Oncology, discusses the implications of the results of the MA17R trial, which is a randomized phase III clinical trial that examined the benefits of extending aromatase inhibitors with letrozole as a treatment for postmenopausal patients with early breast cancer.

Emerging Therapies in ER+ Metastatic Breast Cancer

July 26, 2016

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering, discusses some of the emerging therapies for patients with ER-positive metastatic breast cancer.